Stockreport

GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients [Yahoo! Finance]

GeoVax Labs, Inc.  (GOVX) 
NASDAQ:AMEX Investor Relations: geovax.com/contact-geovax.html
PDF Phase 2 Data Reinforce GEO-CM04S1 as an Important Next-generation Vaccine Candidate for the 40 Million U.S. and 400 Million Global Immunocompromised Patients Underserve [Read more]